Explore more
News
GSK shares fall
Digest more
Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...
GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.
GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback